2024.07.23 (화)

  • 구름많음동두천 24.3℃
  • 흐림강릉 26.6℃
  • 흐림서울 26.1℃
  • 구름많음대전 27.8℃
  • 흐림대구 28.9℃
  • 구름많음울산 28.1℃
  • 흐림광주 27.2℃
  • 흐림부산 27.1℃
  • 흐림고창 27.7℃
  • 맑음제주 28.1℃
  • 맑음강화 23.8℃
  • 구름많음보은 27.3℃
  • 흐림금산 28.0℃
  • 흐림강진군 26.2℃
  • 흐림경주시 29.5℃
  • 구름많음거제 27.6℃
기상청 제공

경제

Apira Science, Inc. Announces Successful Completion of Clinical Trial for the Treatment of Androgenetic Alopecia in Males

NBC-1TV World News

[By NBC-1TV H. J Yook]Apira Science, Inc. today announced that it has successfully completed a clinical trial using its visible red light laser/LED system for promoting hair growth in males. This randomized, double blind, placebo controlled prospective study was conducted at multiple sites in the U.S. The principal investigator was Raymond Lanzafame, MD MBA FACS. The trial was designed to evaluate the efficacy of low level light therapy (LLLT) for promoting hair growth in males diagnosed with androgenetic alopecia of the head.

The clinical trial involved 22 male subjects at two separate sites (44 total subjects) with skin phototypes classified as I-IV on the Fitzpatrick scale with hair loss patterns of IIa-V on the Hamilton-Norwood scale. Subjects were randomly assigned to either the active laser/LED group or the placebo group. All subjects were given a wearable system to take home and use 4 times per week for 25 minutes per session in accordance with the Institutional Review Board (IRB) approved protocol. The primary goal was to demonstrate the percent increase in terminal hair counts from baseline at the end of 16 weeks of treatment.

Commenting on the results of this trial, the principal investigator, Dr. Raymond Lanzafame said, “Research on the use of low level light therapy to treat male pattern baldness is ongoing. In this IRB approved study in male patients with androgenetic alopecia, the preliminary results of low level light therapy demonstrate this treatment strategy is efficacious. It is anticipated that laser and light based technologies will play an important role in managing this condition in the future.”

“We are very pleased with the results of this study which clearly demonstrate the effectiveness of our innovative system,” commented Jeff Braile, director of research at Apira Science, Inc. “This study validates LLLT as a viable treatment option for healthy men with androgenetic alopecia.”



배너

관련기사


배너
배너
배너
배너
배너
배너
배너
배너
배너
배너
배너
배너